Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease
Sponsor: Arrowhead Pharmaceuticals
Listed as NCT05083364, this observational or N/A phase trial focuses on C3 Glomerulopathy and IgA Nephropathy and remains completed. Sponsored by Arrowhead Pharmaceuticals, it has been updated 17 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
May 4, 2026 — Present [daily]
Completed
Phase: PHASE1/PHASE2 → None
-
Jan 2026 — May 2026 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Apr 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1 → PHASE1/PHASE2
▶ Show 12 earlier versions
-
Feb 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE1
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy \[C3G\] and IgA Nephropathy \[IgAN\]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.
Contact Information
- Arrowhead Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Bangkok, Thailand , Camperdown, Australia , Chiang Mai, Thailand , Clayton, Australia , Cologne, Germany , Concord, Australia , Daegu, South Korea , Erlangen, Germany , Gamcheon, South Korea and 6 more locations